The purpose of the study is to determine whether nerandomilast can more effectively delay death or disease worsening compared with the placebo.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year. During this time, they will attend regular clinic visits where doctors will check skin thickness, lung function (including a test called FVC that measures how much air can be forced out of the lungs), physical ability, and overall health. The study will track any serious health events, changes in symptoms, and overall survival throughout the treatment period.

The study is designed to continue treatment for patients who have already participated in previous research with rocatinlimab. Participants will receive either rocatinlimab or placebo through injections under the skin. This is a long-term study that will monitor how well patients maintain improvement in their skin condition and any side effects that may occur during treatment.

The research will track various aspects of the skin condition, including changes in skin appearance, itching severity, and overall symptoms. The study will particularly focus on monitoring the safety of the treatment by recording any side effects and checking laboratory test results and vital signs throughout the treatment period.

The purpose of the study is to see whether lunsekimig can reduce the number of moderate to severe flare‑ups of the lung disease over a year. After enrollment, participants will be randomly assigned to one of the two groups and will attend regular clinic visits for injections, safety checks, and simple breathing tests over several months.

A flare‑up, or exacerbation, means a sudden worsening of breathing problems that often requires extra medication or a hospital visit. The term Forced Expiratory Volume in 1 second refers to a common breathing test that measures how much air a person can force out of their lungs in one second; it helps doctors track lung function. The eosinophilic pattern is identified by a blood test that shows higher eosinophil counts, which can influence how the disease behaves and responds to treatment.

The purpose of the study is to evaluate whether Orelabrutinib can delay the worsening of disability compared with placebo. Participants will receive the assigned tablet each day for several years and will attend regular clinic visits where their ability to perform everyday tasks is checked and brain scans using MRI are performed to look for new lesions. The study will track how long it takes before a confirmed increase in disability occurs and will record any safety concerns throughout the trial.

Participants are randomly assigned to receive either the combination therapy or a single oral drug, and treatment continues until disease progression or unacceptable side effects occur. Visits include regular health checks, blood tests, and imaging scans to monitor the tumor and overall health. The study follows patients for several months to record how long they live, how long the disease stays stable, and any side effects that arise.

The primary aim is to evaluate how well this combination works in controlling the disease. Participants receive the injection and the capsule on a repeated schedule, typically every few weeks, and are followed for several months with regular doctor visits, blood tests, and imaging to check for disease activity and any side effects. The study continues until a predefined number of treatment cycles are completed or if a participant experiences significant toxicity that requires stopping the therapy.

The purpose of the trial is to determine whether the new drug works at least as well as the existing treatment in preserving or improving vision. Vision will be assessed using a standard test called Best-Corrected Visual Acuity, which measures how many letters a person can read on an eye chart, reported in ETDRS letters.

Participants will receive a series of eye injections over roughly one year, with regular visits to check eye health, vision scores, and any side effects. The study is designed so that neither the participants nor the doctors know which medication is being given at each visit.

The purpose of the study is to see whether adding GB-0895 can lower the number of serious asthma attacks over a one‑year period. Volunteers will receive the assigned injection at regular intervals for about 52 weeks and will attend routine visits where doctors will check lung function using simple breathing tests, ask about daily symptoms, and have participants fill out questionnaires that measure how asthma affects daily life and overall well‑being. Terms such as “subcutaneous” mean the medication is delivered under the skin, and “systemic corticosteroids” refer to steroid medicines taken by mouth or injection that help reduce inflammation during severe attacks.

The study follows a short treatment period after semaglutide is given. During this time, the study team checks how well the medicine is tolerated and records common stomach and body symptoms such as nausea, vomiting, constipation, diarrhoea, abdominal pain, dizziness, fatigue, headache, appetite changes, and changes in body weight. The main focus is on how strong nausea is during the first few days after treatment.

The trial is randomised, which means the study treatment is assigned by chance, and double-blind, which means neither the participants nor the study team know who receives which treatment during the study. The trial is also placebo-controlled, so one group receives placebo instead of the active added medicine.

The study is planned in two groups, and neither the participants nor the study team will know which treatment is given. After starting treatment, the medicine is taken for a period of time and then the study looks at changes in urine protein and kidney function over about 20 weeks. The study is designed to compare BI 764198 with placebo across the different kidney disease groups.

People in the study are assigned by chance to receive either orelabrutinib or placebo. The study is set up so that neither the participants nor the study doctors know which treatment is being given during the trial. Treatment is taken over time, and the study follows participants to see how their condition changes during the study period.

PPMS can affect walking, balance, hand use, and other body functions. Disability progression means a gradual increase in these problems. The study is designed to compare how often this worsening happens in the two groups.

The study is a long-term extension, which means it follows people over a longer period after earlier treatment. During the trial, the medicine is taken by mouth and participants are watched over time for side effects and other health changes. Regular checkups and laboratory tests are used to follow general health, joint symptoms, and skin symptoms while treatment continues.

In the study, people are randomly assigned to receive either the new treatment combination or the standard treatment combination. The medicines are given as intravenous infusion, which means they are delivered slowly through a vein. Treatment is given in cycles over time, with regular visits for infusions and checks by the study team. The study will look at how long people live and will also follow symptoms and side effects, including breathing problems, chest pain, cough, and treatment-related reactions such as CRS and ICANS. CRS, or cytokine release syndrome, is a strong immune reaction that can cause fever and other symptoms. ICANS, or immune effector cell-associated neurotoxicity syndrome, is a brain and nerve problem that can affect thinking, speech, or alertness.

Participants may receive different combinations of medications. One group will receive blinatumomab alternating with low-intensity chemotherapy, which is a type of treatment that uses drugs to kill cancer cells. The other group will receive the standard of care, which includes medications such as rituximab, cytarabine, dexamethasone, vincristine sulfate, cyclophosphamide, methotrexate sodium, mercaptopurine, prednisone, idarubicin, asparaginase, and doxorubicin. Other substances mentioned in the study include pegaspargase, crisantaspase, and prednisolone.

The study will monitor how long patients live and how long they stay without the cancer returning. Researchers will also look at the minimal residual disease, which refers to the small number of cancer cells that remain in the body after treatment. Additionally, the study will track how the treatments affect the patients’ quality of life, including levels of pain, tiredness, and physical function.

The purpose of the study is to compare the effectiveness of different medication combinations in preventing the cancer from getting worse. One group will receive a combination of sotorasib, panitumumab, and FOLFIRI. FOLFIRI is a treatment plan that includes fluorouracil, irinotecan hydrochloride trihydrate, and calcium folinate, all of which are administered through intravenous use, meaning they are delivered directly into a vein. Another group will receive FOLFIRI either alone or combined with bevacizumab.

Participants will be assigned to one of these treatment groups to see which approach is better at managing the disease. The study will follow the progress of the cancer over time to observe how long the treatments keep the disease from spreading further or increasing in size.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

Participants in this trial will receive either the study drug, remibrutinib, in the form of a film-coated tablet taken by mouth, or a placebo. The purpose of the study is to determine if this treatment can help delay the progression of disability. During the study, individuals will be monitored over a period of time to observe how the medication affects their physical abilities and overall health.

During the study, participants will be monitored over a period of time to see how the medication affects the occurrence of major health events. These events include myocardial infarction, commonly known as a heart attack, stroke, or being hospitalized due to heart failure. The study also looks at coronary revascularization, which is a procedure used to improve blood flow to the heart, and any deaths caused by any reason.

During the course of this research, participants will receive regular doses of the study drug to observe how it affects the body over an extended period. Medical professionals will monitor various aspects of health, including vital signs such as blood pressure and heart rate, as well as electrocardiogram results, which are tests that record the electrical activity of the heart. Additionally, regular blood tests will be performed to check hematology and clinical chemistry, which are used to examine the components of the blood and the chemical balance in the body.

The study involves healthy participants aged 16 to 40 years. Participants will receive the mRNA-1647 vaccine or a placebo through a series of three injections. The trial will monitor participants over a period of time to see if the vaccine can prevent CMV infection and to check for any side effects. The study will also involve the use of Sodium Chloride 0.9%, which is a common solution used in medical settings, as part of the injection process.

The main goal of the study is to demonstrate the effectiveness of the mRNA-1647 vaccine in preventing CMV infection in participants who have not been previously exposed to the virus. The trial will also assess the safety of the vaccine and how well it is tolerated by participants. This research is important for developing new ways to protect people from CMV and improve public health outcomes.

The purpose of the study is to evaluate how well these treatments work and how safe they are for patients. Participants will receive either Zilovertamab Vedotin alone or together with Nemtabrutinib. Zilovertamab Vedotin is given as an injection into a vein, while Nemtabrutinib is taken as a tablet by mouth. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients.

The study will take place over several weeks, during which participants will be closely monitored by healthcare professionals. They will undergo regular check-ups and tests to assess their response to the treatment and to ensure their safety. The study aims to provide valuable information that could lead to better treatment options for people with these types of blood cancers.

The purpose of this study is to show whether empasiprubart works better than human normal immunoglobulin in improving the ability to perform daily activities in adults with this nerve condition. During the study, participants will be randomly assigned to receive either empasiprubart or human normal immunoglobulin through a vein. The study uses a double-dummy design, which means that all participants will receive two infusions to ensure that neither the participants nor the doctors know which treatment is being given. The main assessment will happen at week 24, when doctors will measure changes in functional ability using a scoring system that evaluates arm and leg function.

Throughout the study, various measurements will be taken to assess how well participants can perform daily tasks, their muscle strength, their walking ability, and their overall quality of life. Grip strength will be measured regularly, and participants will complete questionnaires about their disability, fatigue, pain, and general health status. Blood samples will be taken to measure drug levels and to check for any immune responses to the treatment. Safety will be monitored by tracking any unwanted effects, changes in laboratory tests, heart rhythm recordings, and vital signs. The study will also look at how the treatments affect specific proteins in the blood that are involved in the immune response and nerve damage.

The study will test a medication called glepaglutide, which is given as an injection under the skin twice each week. Some participants will receive glepaglutide while others will receive placebo. The purpose of this study is to confirm whether glepaglutide can help reduce the amount of parenteral support that people with short bowel syndrome need each week. The study will look at whether the medication can decrease the volume of nutrition and fluids that must be given through the veins, and possibly help some people reduce the number of days per week they need this support or even stop needing it completely.

The study is divided into two parts. In the first part, which lasts 24 weeks, participants will be randomly assigned to receive either glepaglutide or placebo, and neither the participants nor the doctors will know which treatment is being given. This part will continue for up to 52 weeks for some measurements. After this, there will be a longer period where all participants will receive glepaglutide and everyone will know they are receiving the actual medication. During the study, doctors will measure changes in the weekly volume of parenteral support needed and track how participants feel about their condition overall.

The purpose of this study is to find out if adding bleximenib to the standard intensive chemotherapy treatment can help patients live longer without their disease getting worse compared to receiving standard chemotherapy with placebo. The standard treatment includes chemotherapy to put the disease into remission, followed by additional chemotherapy to strengthen this response, and then maintenance therapy to help keep the disease under control.

During the study, patients will receive either bleximenib or placebo together with their regular intensive chemotherapy treatment. The study follows patients through the initial treatment phase aimed at achieving remission, a consolidation phase to reinforce the response, and then a maintenance phase. Neither the patients nor their doctors will know whether they are receiving bleximenib or placebo during the study. The study will monitor how well the treatment works and track patient outcomes over time.

The purpose of this study is to find out if camizestrant, either alone or combined with abemaciclib, works better than standard hormone treatments, either alone or combined with abemaciclib, in preventing breast cancer from coming back. The study will measure how long people remain free from invasive breast cancer returning. People taking part in this study will be assigned by chance to receive either camizestrant or one of the standard hormone treatments. The treatment will continue for a period of time, and people will be monitored regularly to check how well the treatment is working and to watch for any unwanted effects.

During the study, doctors will check for any side effects that occur, perform blood tests, and measure vital signs like blood pressure and heart rate. People in the study will also be asked questions about their quality of life and how the side effects of treatment affect them in their daily lives. Blood samples may be taken to measure the amount of camizestrant in the blood. The study will track whether the cancer comes back, spreads to other parts of the body, or if a new cancer develops, as well as overall survival.

The purpose of the study is to see if empasiprubart can help improve the ability to perform daily activities compared to placebo. The study will also look at how safe the medication is and how well it is tolerated by people with this nerve condition. Researchers want to understand if this treatment can help reduce disability and improve quality of life for people living with this condition.

The study is divided into two parts and will last up to about two years for each person who takes part. During the study, empasiprubart will be given through a needle into a vein, which is called an infusion. People taking part will have regular visits where doctors will check their muscle strength, ability to perform daily tasks, grip strength, and overall well-being. The study will also measure various safety aspects including blood tests, heart function tests, and any side effects that may occur. Throughout the study, researchers will collect blood samples to measure the levels of the medication in the body and to see how the immune system responds to the treatment.

The purpose of the study is to find out what dose of GSK4524101 can be given safely, either alone or together with niraparib, and to see if the combination of these two drugs can help slow down or stop the growth of cancer. The study is divided into two parts. In the first part, small groups of people will receive increasing doses of GSK4524101 alone or combined with niraparib to find the highest dose that can be given without causing serious side effects. This part will also include a group to test whether taking GSK4524101 with food affects how the body processes the medication. In the second part, a larger group of people with the specific type of breast cancer described above will receive the combination of GSK4524101 and niraparib at a dose determined to be safe from the first part, to learn more about whether this combination can help shrink tumors.

Throughout the study, participants will have regular check-ups where doctors will monitor for any side effects and take blood samples to measure the amount of medication in the body. The study will also assess how well the treatment works by looking at whether tumors shrink or stop growing, and how long any positive effects last. Participants in the first part will help determine the safest dose to use, while those in the second part will help show whether the combination treatment can provide benefit for people with this specific type of breast cancer who have not previously received a PARP inhibitor.

People taking part in this study will already be receiving treatment for their condition with either steroid medications taken by mouth or immunoglobulin therapy given through a vein or under the skin. During the study, participants will be checked regularly to see if their symptoms worsen or stay stable. The study will look at different measures of how well people can perform daily activities and how strong their muscles are, including grip strength in the dominant hand and overall muscle strength.

The study will last for several years and will involve multiple visits where various assessments will be done. The main focus will be on measuring whether people remain free from worsening of their condition over a period of 24 weeks. Other measurements will include changes in the ability to perform daily tasks, hand grip strength, and overall muscle strength at the same time point.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The purpose of this study is to determine if combining these chemotherapy drugs with precisely targeted radiation therapy (called stereotactic ablative radiotherapy) can help control cancer that has spread to a limited number of locations in the body. The treatment involves receiving chemotherapy through an intravenous infusion, along with radiation therapy directed at specific tumor sites identified through specialized imaging scans.

This is a two-phase study where doctors first evaluate the safety of this treatment combination, and then assess how well it works at controlling the cancer. The study is designed for patients who have already tried other standard treatments and have limited remaining treatment options. The treatment approach aims to target both widespread disease with chemotherapy and specific tumor sites with focused radiation therapy.

The study will test a medication called cemiplimab (also known as LIBTAYO), which is given through an intravenous infusion. This medicine belongs to a group of drugs called immunotherapy, which helps the body’s immune system fight cancer cells. The purpose is to determine if giving cemiplimab after surgery can help prevent the cancer from returning, compared to patients who receive no additional treatment after surgery.

During the study, participants will either receive cemiplimab treatment or be observed without treatment. The medication will be given through an infusion into a vein every few weeks. The total treatment period may last up to 42 weeks. Doctors will monitor the participants’ health and check if the cancer returns during and after the treatment period.

Multiple Myeloma is a type of blood cancer that affects plasma cells, which are special white blood cells that help fight infections. The study aims to determine which treatment combination is more effective at eliminating cancer cells to a level that cannot be detected by very sensitive testing methods.

The medications used in this study are given in different ways. Lenalidomide is taken by mouth in capsule form, while Daratumumab and Linvoseltamab are given through an infusion into a vein. Dexamethasone can be given either as tablets by mouth or as an injection. The treatment continues for several weeks, and patients will need regular visits to the hospital for monitoring and receiving their medications.

The purpose of this research is to assess how safe and well-tolerated NBI-1065845 is when taken as an additional treatment alongside regular antidepressant medication. The study medication comes in the form of oral tablets that participants take along with their current antidepressant treatment.

This is a long-term study that lasts for approximately 52 weeks (one year). During this time, all participants receive the study medication NBI-1065845 while continuing their current antidepressant treatment at the same dose they were taking before joining the study. The study team monitors participants’ health and any side effects that may occur throughout the treatment period.

The study involves two phases. In the first phase, all participants receive NBI-1065845 along with their current antidepressant medication. Those who show improvement then continue to the second phase, where they are randomly assigned to either continue taking NBI-1065845 or receive a placebo, while maintaining their regular antidepressant medication. The treatment period lasts for 33 months.

The medication being studied, NBI-1065845, comes in tablet form and is taken by mouth. This research specifically looks at people who have experienced recurring episodes of moderate to severe depression or have persistent depressive symptoms, despite being on antidepressant treatment. The study will track how long it takes for depression symptoms to return, if they do, after participants start the second phase of the study.

The study aims to determine if the new chickenpox vaccine and Priorix work equally well when given as muscle injections compared to the standard under-the-skin method. The effectiveness will be measured by testing the body’s immune response to the vaccines through blood tests taken 43 days after vaccination.

During the study, participants will be monitored for common vaccination reactions like redness, pain, and swelling at the injection site, as well as general symptoms such as drowsiness, decreased appetite, irritability, and fever. They will also be checked for any rashes that may develop after vaccination. The total study duration will be 181 days, during which participants will have regular check-ups to monitor their health and any side effects.

The study involves three groups of participants. Some patients will receive Debio 4126 through intramuscular injection, while others will receive a placebo. The third group will receive Debio 4126 in an open-label manner, meaning both the doctor and patient know which treatment is being given. The medication will be administered every 12 weeks, and patients will be monitored for changes in their IGF-1 levels and overall health throughout the study period.

The treatment may also include other medications such as lanreotide for some participants. Throughout the study, doctors will monitor the safety of the treatment by checking various health parameters, including blood tests, vital signs, and the size of the pituitary tumor. They will also evaluate how well patients tolerate the injections by assessing any reactions at the injection site.

The purpose of this study is to determine whether risankizumab is as effective as or more effective than vedolizumab for treating ulcerative colitis over a 48-week period. Participants in this study will have already tried other conventional treatments such as aminosalicylates (anti-inflammatory drugs), steroids, or immunomodulators without adequate relief of their symptoms.

During the study, participants will be randomly assigned to receive either risankizumab or vedolizumab. The study will monitor improvements in the intestinal lining through endoscopy (a procedure where a small camera is used to examine the inside of the colon) and track symptom improvement including stool frequency and rectal bleeding. This is an open-label study, meaning both the healthcare providers and participants will know which medication is being administered.

The main purpose of this research is to determine if empasiprubart is effective at improving muscle strength compared to intravenous immunoglobulin in people with Multifocal Motor Neuropathy. Both medications will be given through intravenous infusion, which means they are administered directly into a vein.

The study is divided into two parts. During the treatment period, participants will receive either empasiprubart or intravenous immunoglobulin along with their matching placebos. Throughout the study, doctors will measure changes in muscle strength and other aspects of the condition. The research team will also monitor the safety of the treatments and collect information about how well participants feel and function in their daily activities.

The research will assess whether rocatinlimab can improve the condition of patients’ skin by reducing the severity and affected areas of eczema. The study will measure improvements in skin appearance, reduction in pruritus (itching), decrease in skin pain, and overall quality of life for participants. It will specifically examine whether participants achieve clear or almost clear skin on their face, hands, and other body areas after treatment.

Throughout the 24-week study period, participants will receive either rocatinlimab or placebo and will need to regularly report their symptoms and complete assessments. The research is designed for adults who have had atopic dermatitis for at least 12 months and have not responded adequately to previous treatments for their condition.

The purpose of the study is to determine if the new high-dose vaccine is at least as effective as the existing vaccine in producing an immune response. Participants will receive either the new vaccine or the existing one through an injection. The study will monitor the immune response by measuring specific antibodies in the blood 28 days after vaccination. Participants will also be observed for any side effects or adverse reactions following the vaccination.

The study will take place over several months, with participants being followed up to six months after receiving the vaccine. This will help researchers gather comprehensive data on the vaccine’s safety and its ability to trigger a strong immune response. The ultimate goal is to ensure that the new high-dose vaccine provides effective protection against influenza in older adults, who are at higher risk for complications from the flu.